Zacks Research Brokers Boost Earnings Estimates for Biogen

Biogen Inc. (NASDAQ:BIIB) – Research analysts at Zacks Research increased their Q1 2026 earnings per share estimates for shares of Biogen in a research report issued on Wednesday, October 22nd. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings per share of $3.47 for the quarter, up from their prior estimate of $3.45. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Biogen’s Q2 2026 earnings at $3.79 EPS, Q4 2026 earnings at $3.94 EPS, FY2026 earnings at $14.87 EPS, Q2 2027 earnings at $3.96 EPS, Q3 2027 earnings at $4.01 EPS and FY2027 earnings at $15.88 EPS.

Biogen (NASDAQ:BIIB) last issued its earnings results on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share for the quarter, topping the consensus estimate of $3.93 by $1.54. Biogen had a return on equity of 13.85% and a net margin of 15.31%.The business had revenue of $2.65 billion for the quarter, compared to analysts’ expectations of $2.32 billion. During the same period in the previous year, the firm posted $5.28 EPS. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS.

BIIB has been the subject of a number of other research reports. Citigroup reissued a “neutral” rating on shares of Biogen in a report on Wednesday, September 24th. Truist Financial started coverage on Biogen in a report on Monday, July 21st. They issued a “hold” rating and a $142.00 price objective on the stock. Wall Street Zen upgraded Biogen from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 28th. Royal Bank Of Canada cut their price target on shares of Biogen from $219.00 to $217.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 8th. Finally, Morgan Stanley raised their price target on shares of Biogen from $144.00 to $149.00 and gave the company an “equal weight” rating in a research report on Friday, October 10th. Eleven investment analysts have rated the stock with a Buy rating, nineteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $180.69.

Biogen Stock Up 1.0%

Shares of BIIB opened at $147.72 on Thursday. Biogen has a 52-week low of $110.04 and a 52-week high of $187.58. The company has a quick ratio of 1.79, a current ratio of 2.50 and a debt-to-equity ratio of 0.36. The stock has a fifty day simple moving average of $142.50 and a two-hundred day simple moving average of $131.81. The company has a market capitalization of $21.66 billion, a PE ratio of 14.12, a price-to-earnings-growth ratio of 1.16 and a beta of 0.13.

Institutional Trading of Biogen

Institutional investors have recently modified their holdings of the stock. Elevation Point Wealth Partners LLC purchased a new stake in Biogen in the second quarter valued at $25,000. Vision Financial Markets LLC purchased a new position in shares of Biogen during the first quarter worth about $27,000. Greykasell Wealth Strategies Inc. acquired a new stake in shares of Biogen during the first quarter worth about $27,000. Rothschild Investment LLC lifted its holdings in shares of Biogen by 64.7% in the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 88 shares during the last quarter. Finally, Zions Bancorporation National Association UT purchased a new position in Biogen during the 1st quarter worth approximately $29,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Insider Activity

In other news, insider Priya Singhal sold 517 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $133.55, for a total value of $69,045.35. Following the transaction, the insider owned 5,772 shares in the company, valued at approximately $770,850.60. This represents a 8.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.18% of the company’s stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.